This study is testing a new medicine called sovilnesib for people with a type of ovarian cancer that doesn't respond to regular medicine anymore. The study has two parts. In Part 1, up to 10 people will try different doses of sovilnesib to see how safe it is and how well it works. In Part 2, 20-30 more people will continue testing the doses to find the best one. The medicine is taken by mouth in a 28-day cycle. If you join, you'll need to have regular check-ups to make sure the medicine is safe and helping. Some risks are involved, and you can stop anytime if needed.
- Study involves up to 40 participants, with treatment lasting in 28-day cycles.
- Participants must be 18 or older with specific types of ovarian cancer.
- Regular safety checks and evaluations will be conducted during the study.
Eligibility is strict; certain health conditions may prevent participation. This study aims to find the best dose to help future patients with similar cancer types.
How understandable was the trial content above?
Hard to understand
Easy to understand